- Home
- ARDX vs GRDN Comparison
ARDX vs GRDN Comparison
Compare ARDX & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- GRDN
- Stock Information
- Founded
- ARDX 2007
- GRDN 2004
- Country
- ARDX United States
- GRDN United States
- Employees
- ARDX N/A
- GRDN N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- ARDX Health Care
- GRDN Consumer Staples
- Exchange
- ARDX Nasdaq
- GRDN Nasdaq
- Market Cap
- ARDX 1.3B
- GRDN N/A
- IPO Year
- ARDX 2014
- GRDN 2024
- Fundamental
- Price
- ARDX $3.64
- GRDN $25.48
- Analyst Decision
- ARDX Strong Buy
- GRDN Strong Buy
- Analyst Count
- ARDX 8
- GRDN 2
- Target Price
- ARDX $10.19
- GRDN $23.00
- AVG Volume (30 Days)
- ARDX 6.4M
- GRDN 86.3K
- Earning Date
- ARDX 05-01-2025
- GRDN 05-12-2025
- Dividend Yield
- ARDX N/A
- GRDN N/A
- EPS Growth
- ARDX N/A
- GRDN N/A
- EPS
- ARDX N/A
- GRDN N/A
- Revenue
- ARDX $361,706,000.00
- GRDN $1,228,409,000.00
- Revenue This Year
- ARDX $15.74
- GRDN $11.36
- Revenue Next Year
- ARDX $34.56
- GRDN $2.63
- P/E Ratio
- ARDX N/A
- GRDN N/A
- Revenue Growth
- ARDX 127.33
- GRDN 17.42
- 52 Week Low
- ARDX $3.62
- GRDN $14.16
- 52 Week High
- ARDX $9.20
- GRDN $26.91
- Technical
- Relative Strength Index (RSI)
- ARDX 32.40
- GRDN N/A
- Support Level
- ARDX $3.62
- GRDN N/A
- Resistance Level
- ARDX $5.65
- GRDN N/A
- Average True Range (ATR)
- ARDX 0.31
- GRDN 0.00
- MACD
- ARDX -0.15
- GRDN 0.00
- Stochastic Oscillator
- ARDX 6.53
- GRDN 0.00
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.